Genomtec S.A.
Warsaw Stock Exchange GMT.WA
Genomtec S.A. Return on Assets (ROA) for the year ending December 31, 2023: -56.43%
-
Genomtec S.A. Return on Assets (ROA) for the year ending December 31, 2022 was -101.12%, a 39.50% change year over year.
-
Genomtec S.A. Return on Assets (ROA) for the year ending December 31, 2021 was -167.14%, a -44.36% change year over year.
-
Genomtec S.A. Return on Assets (ROA) for the year ending December 31, 2020 was -115.78%, a -132.65% change year over year.
-
Genomtec S.A. Return on Assets (ROA) for the year ending December 31, 2019 was -49.77%.
| Date | Return on Assets (ROA) | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Mr. Miron Tokarski Ph.D. |
| IPO Date | March 17, 2021 |
| Location | Poland |
| Headquarters | Bierutowska Street 57-59 |
| Employees | 17 |
| Sector | Healthcare |
| Industries | |
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email